Catumaxomab for the Treatment of Malignant Ascites in Patients With Chemotherapy-Refractory Ovarian Cancer

Berek, Jonathan S.; Edwards, Robert P.; Parker, Lynn P.; DeMars, Leslie R.; Herzog, Thomas J.; Lentz, Samuel S.; Morris, Robert T.; Akerley, Wallace; Holloway, Robert W.; Method, Michael; Plaxe, Steven C.; Walker, Joan L.; Friccius-Quecke, H.; Krasner, Carolyn

doi:10.1097/igc.0000000000000286

Cited by 45 publications

(18 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This allows immune cells to colocalize with tumour and cause cytotoxicity. EpCAM positive cells are found in 70-100% of malignant effusions and in a phase II study intraperitoneal (IP) administration of catumaxomab significantly improved the puncture free interval in heavily pre-treated patients [81]. It was given EMA approval for IP administration but the manufacturer withdrew this for commercial reasons in July 2017.…”

Section: Other Approachesmentioning

confidence: 99%

Novel Systemic Treatments in High Grade Ovarian Cancer

Samani¹,

Chan²,

Krell³

2018

Ovarian Cancer - From Pathogenesis to Treatment

View full text Add to dashboard Cite

Most patients with ovarian cancer present at an advanced stage and are never cured. To improve outcomes a variety of novel systemic strategies are being developed. Traditional cytotoxic chemotherapy is being optimised, anti-angiogenic strategies are already in the clinic and several PARP inhibitors have gained regulatory approval. In addition, immunotherapy is showing promise and novel targeted strategies including against folate receptor alpha are also generating excitement. As our therapeutic choice increases, a challenge will be how to best utilize the options available. Here we discuss recently established and other emerging therapies with a focus on key concepts rather than detailed synopses of trial designs and outcomes.

show abstract

Section: Other Approachesmentioning

confidence: 99%

Novel Systemic Treatments in High Grade Ovarian Cancer

Samani¹,

Chan²,

Krell³

2018

Ovarian Cancer - From Pathogenesis to Treatment

View full text Add to dashboard Cite

show abstract

“…In a randomized Phase II/III study including 129 patients, puncture-free survival was significantly longer in the group receiving catumaxomab [ 19 ]. Recently, a Phase II study of catumaxomab in chemotherapy-refractory ovarian cancer patient with malignant ascites demonstrated a benefit for catumaxomab therapy: catumaxomab prolonged both the puncture free interval and the time to first therapeutic puncture as well as producing improvement in quality of life [ 20 ].…”

Section: Antibody Therapymentioning

confidence: 99%

Immunotherapeutic approaches to ovarian cancer treatment

Chester¹,

Dorigo²,

Berek³

et al. 2015

j. immunotherapy cancer

View full text Add to dashboard Cite

Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for ovarian cancer patients are inadequate. Immunotherapy offers a novel and promising therapeutic strategy for treating ovarian tumors. Following the demonstration of the immunogenicity of ovarian tumors, multiple immunotherapeutic modalities have been developed. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor-modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery.

show abstract

“…Therefore, various immunotherapeutic approaches for ovarian cancer including antibodies, immune checkpoint inhibitors, vaccines, and adoptive cell therapy have recently entered clinical testing (6). Bevacizumab and cetuximab are among monoclonal antibodies which showed promising results in clinical trials (18,19). Immune checkpoints are specific molecules with the ability to inhibit powerful immunologic effector cells.…”

Section: Immunotherapy In Ovarian Cancermentioning

confidence: 99%

Cancer-Testis Antigens: A Novel Group of Tumor Biomarkers in Ovarian Cancers

et al. 2016

View full text Add to dashboard Cite

Context: Ovarian cancer is the most fatal gynecological malignancy with no effective screening strategy for early detection. As most cases are being detected in advance stages, conventional therapies are not beneficial for the majority of patients. Cancer-testis antigens (CTAs) are a group of tumor associated antigens with specific expression pattern in cancers which potentiate them for application as cancer biomarkers and targets for immunotherapy. Evidence Acquisition: We performed a computerized search of the MEDLINE/PUBMED databases with key words: ovarian cancer, cancer-testis antigen, biomarker and immunotherapy.

show abstract

Catumaxomab for the Treatment of Malignant Ascites in Patients With Chemotherapy-Refractory Ovarian Cancer

Abstract: Catumaxomab prolonged PuFI and TTPu had a beneficial effect on quality of life, as shown by the improvement in ascites symptoms, and had an acceptable safety profile, which is consistent with its mode of action.

Cited by 45 publications

References 30 publications

Novel Systemic Treatments in High Grade Ovarian Cancer

Novel Systemic Treatments in High Grade Ovarian Cancer

Immunotherapeutic approaches to ovarian cancer treatment

Cancer-Testis Antigens: A Novel Group of Tumor Biomarkers in Ovarian Cancers

Contact Info

Product

Resources

About